Anaptysbio Share Price Today
(NASDAQ: ANAB)

Name: Anaptysbio Share Price Today (NASDAQ: ANAB) - Anaptysbio Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Anaptysbio share price is $16.75 & ₹1,456.73 as on 6 Mar 2025, 2.30 'hrs' IST

$16.75

▲

1.5

(9.84%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Anaptysbio share price in Dollar and Rupees. Guide to invest in Anaptysbio stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Anaptysbio, along with analyst recommendations, forecasts, and comprehensive financials.

Anaptysbio share price movements

Today's Low: $15.14
Today's High: $16.76
$16.75
9.61%
Downside
Day's Volatility :9.67%
Upside
0.06%
52 Weeks Low: $12.21
52 Weeks High: $41.31
$16.75
27.1%
Downside
52 Weeks Volatility :70.44%
Upside
59.45%

Anaptysbio (ANAB) Returns

Period	Anaptysbio Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-35.55%	2.1%	0.0%
6 Months	-58.55%	-4.1%	0.0%
1 Year	-40.17%	2.2%	0.0%
3 Years	-49.17%	11.8%	-11.6%

Anaptysbio (ANAB) Key Statistics

in dollars & INR

Previous Close	$15.25
Open	$15.35
Today's High	$16.76
Today's Low	$15.14
Market Capitalization	$449.0M
Today's Volume	$197.2K
52 Week High	$41.3083
52 Week Low	$12.21
Revenue TTM	$91.3M
EBITDA	$-114.3M
Earnings Per Share (EPS)	$-6.05
Profit Margin	-159.1%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-182.71%

How to invest in Anaptysbio Stock (ANAB) from India?

It is very easy for Indian residents to invest directly in Anaptysbio from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Anaptysbio stock in both Indian Rupees (INR) and US Dollars (USD). Search for Anaptysbio or ANAB on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Anaptysbio or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Anaptysbio shares which would translate to 0.052 fractional shares of Anaptysbio as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Anaptysbio, in just a few clicks!

Returns in Anaptysbio (ANAB) for Indian investors in Rupees

The Anaptysbio stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Anaptysbio investment value today

Current value as on today

₹70,675

Returns

₹29,325

(-29.33%)

Returns from Anaptysbio Stock

₹34,288 (-34.29%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Anaptysbio (ANAB)

127%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Anaptysbio Stock from India on INDmoney has increased by 127% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Anaptysbio

EcoR1 Capital, LLC
25.67%
FMR Inc
9.88%
BlackRock Inc
8.31%
Vanguard Group Inc
6.01%
Fairmount Funds Management LLC
5.92%
TANG CAPITAL MANAGEMENT LLC
4.34%

Analyst Recommendation on Anaptysbio

Buy

75%Buy

25%Hold

0%Sell

Based on 16 Wall street analysts offering stock ratings for Anaptysbio(by analysts ranked 0 to 5 stars)

Based on 16 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Anaptysbio Stock (ANAB)

What analysts predicted

Upside of 121.44%

Target:

$37.09

Current:

$16.75

Insights on Anaptysbio Stock (Ticker Symbol: ANAB)

Price Movement
In the last 6 months, ANAB stock has moved down by -58.5%
Increasing Revenue
Revenue is up for the last 4 quarters, 7.17M → 43.11M (in $), with an average increase of 42.8% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -46.66M → -21.78M (in $), with an average increase of 46.4% per quarter
ANAB vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 102.1%
ANAB vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 97.3%
Price to Sales
ForANAB every $1 of sales, investors are willing to pay $4.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

ANAB Anaptysbio Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$8.0M	↑ 60.0%
Net Income	$-97.3M	↑ 57.87%
Net Profit Margin	-1.2K%	↑ 16.42%

	FY20	Y/Y Change
Revenue	$75.0M	↑ 837.5%
Net Income	$-19.9M	↓ 79.53%
Net Profit Margin	-26.56%	↑ 1190.14%

	FY21	Y/Y Change
Revenue	$63.2M	↓ 15.77%
Net Income	$-57.2M	↑ 187.11%
Net Profit Margin	-90.53%	↓ 63.97%

	FY22	Y/Y Change
Revenue	$10.3M	↓ 83.72%
Net Income	$-128.7M	↑ 125.07%
Net Profit Margin	-1.3K%	↓ 1160.8%

	FY23	Y/Y Change
Revenue	$17.2M	↑ 66.78%
Net Income	$-163.6M	↑ 27.11%
Net Profit Margin	-953.66%	↑ 297.67%

	FY24	Y/Y Change
Revenue	$91.3M	↑ 432.03%
Net Income	$-145.2M	↓ 11.24%
Net Profit Margin	-159.1%	↑ 794.56%

	Q3 FY23	Q/Q Change
Revenue	$3.3M	↓ 4.1%
Net Income	$-37.3M	↓ 6.37%
Net Profit Margin	-1.1K%	↑ 27.18%

	Q4 FY23	Q/Q Change
Revenue	$9.0M	↑ 171.4%
Net Income	$-42.2M	↑ 13.14%
Net Profit Margin	-468.75%	↑ 655.66%

	Q1 FY24	Q/Q Change
Revenue	$7.2M	↓ 20.28%
Net Income	$-43.9M	↑ 4.09%
Net Profit Margin	-612.01%	↓ 143.26%

	Q2 FY24	Q/Q Change
Revenue	$11.0M	↑ 52.82%
Net Income	$-46.7M	↑ 6.2%
Net Profit Margin	-425.3%	↑ 186.71%

	Q3 FY24	Q/Q Change
Revenue	$30.0M	↑ 173.6%
Net Income	$-32.9M	↓ 29.59%
Net Profit Margin	-109.44%	↑ 315.86%

	Q4 FY24	Q/Q Change
Revenue	$43.1M	↑ 43.63%
Net Income	$-21.8M	↓ 33.69%
Net Profit Margin	-50.53%	↑ 58.91%

	FY19	Y/Y Change
Profit	$-91.3M	↓ 1926.76%

	FY20	Y/Y Change
Profit	$-5.0M	↓ 94.5%

	FY21	Y/Y Change
Profit	$-35.3M	↑ 602.91%

	FY22	Y/Y Change
Profit	$8.0M	↓ 122.51%

	FY23	Y/Y Change
Profit	$14.8M	↑ 85.88%

	FY24	Y/Y Change
Profit	$91.3M	↑ 517.55%

	Q3 FY23	Q/Q Change
Profit	$2.7M	↓ 5.12%

	Q4 FY23	Q/Q Change
Profit	$8.4M	↑ 208.18%

	Q1 FY24	Q/Q Change
Profit	$6.6M	↓ 21.75%

	Q2 FY24	Q/Q Change
Profit	$10.4M	↑ 57.83%

	Q3 FY24	Q/Q Change
Profit	$29.4M	↑ 183.55%

	FY19	Y/Y Change
Operating Cash Flow	$-69.5M	↑ 43.32%
Investing Cash Flow	$131.4M	↓ 192.26%
Financing Cash Flow	$-4.5M	↓ 102.01%

	FY20	Y/Y Change
Operating Cash Flow	$-14.2M	↓ 79.64%
Investing Cash Flow	$94.5M	↓ 28.12%
Financing Cash Flow	$-879.0K	↓ 80.44%

	FY21	Y/Y Change
Operating Cash Flow	$-45.9M	↑ 224.36%
Investing Cash Flow	$38.8M	↓ 58.89%
Financing Cash Flow	$252.3M	↓ 28802.84%

	FY22	Y/Y Change
Operating Cash Flow	$-73.6M	↑ 60.26%
Investing Cash Flow	$-394.8M	↓ 1116.72%
Financing Cash Flow	$44.0M	↓ 82.55%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-36.5M	↑ 43.55%
Investing Cash Flow	$30.6M	↓ 249.77%
Financing Cash Flow	$-3.1M	↓ 77.23%

Anaptysbio Technicals Summary

Sell

Neutral

Buy

Anaptysbio is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Anaptysbio (ANAB) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Anaptysbio Inc	-7.63%	-58.55%	-40.17%	-49.17%	-7.91%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Anaptysbio Inc	NA	NA	0.0	-5.52	-1.83	-0.15	NA	2.33
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Anaptysbio Inc	Buy	$449.0M	-7.91%	NA	-159.1%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Anaptysbio

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Organization	Anaptysbio
Employees	136
CEO	Mr. Daniel R. Faga
Industry	Health Technology

Management People of Anaptysbio

Name	Title
Mr. Daniel R. Faga	President, CEO & Director
Mr. Eric J. Loumeau	Chief Legal Officer
Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.	Chief Medical Officer
Mr. Dennis M. Mulroy	Chief Financial Officer
Ms. Beth Mueller	Senior Vice President of Human Resources
Dr. Martin Dahl Ph.D.	Senior Vice President of Research
Mr. Benjamin Stone	Chief Business Officer
Mr. Douglas A. Rich M.B.A.	Senior Vice President of CMC
Ms. Monique Da Silva	Senior Vice President of Corporate Affairs
Ms. Priya Raina	Senior Vice President of Clinical Operations

Important FAQs about investing in ANAB Stock from India :

What is Anaptysbio share price today?

Anaptysbio share price today stands at $16.75, Open: $15.35 ; Previous Close: $15.25 ; High: $16.76 ; Low: $15.14 ; 52 Week High: $41.31 ; 52 Week Low: $12.21.

The stock opens at $15.35, after a previous close of $15.25. The stock reached a daily high of $16.76 and a low of $15.14, with a 52-week high of $41.31 and a 52-week low of $12.21.

Can Indians buy Anaptysbio shares?

Yes, Indians can invest in the Anaptysbio (ANAB) from India.

With INDmoney, you can buy Anaptysbio at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Anaptysbio at zero transaction cost.

How can I buy Anaptysbio shares from India?

It is very easy to buy Anaptysbio from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Anaptysbio (ANAB) be purchased?

Yes, you can buy fractional shares of Anaptysbio with INDmoney app.

What are the documents required to start investing in Anaptysbio stocks?

To start investing in Anaptysbio, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.